• Users Online: 160
  • Print this page
  • Email this page
Year : 2019  |  Volume : 6  |  Issue : 4  |  Page : 200-202

Liquefaction of metastatic radioactive iodine-refractory follicular thyroid carcinoma following radiotherapy and sorafenib

1 Department of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan
2 Department of Hematology and Oncology; School of Pharmacy, China Medical University, Taichung, Taiwan

Correspondence Address:
Dr. Chen-Yuan Lin
Department of Hematology and Oncology, China Medical University Hospital, No. 2, Yu-Der Rd., Taichung City 40447
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCRP.JCRP_19_19

Rights and Permissions

Sorafenib was approved for radioactive iodine (RAI)-refractory metastatic differentiated thyroid carcinoma in 2013. Herein, we describe the first case of metastatic RAI-refractory follicular thyroid carcinoma that markedly improved with liquefaction after radiotherapy and low-dose sorafenib use (200 mg twice daily).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded69    
    Comments [Add]    
    Cited by others 1    

Recommend this journal